نتایج جستجو برای: androgen antagonist

تعداد نتایج: 82143  

Journal: :Environmental Health Perspectives 2003
Kanji Yamasaki Masakuni Sawaki Ryo Ohta Hirokazu Okuda Seiichi Katayama Tomoya Yamada Takafumi Ohta Tadashi Kosaka William Owens

The Organisation for Economic Co-operation and Development has initiated the development of new guidelines for the screening and testing of potential endocrine disruptors. The Hershberger assay is one of the assays selected for validation based on the need for in vivo screening to detect androgen agonists or antagonists by measuring the response of five sex accessory organs and tissues of castr...

2013
Ferenc G Rick Norman L Block Andrew V Schally

Androgen deprivation therapy remains the mainstay of medical treatment for advanced prostate cancer. Commonly, this is achieved with medical androgen deprivation rather than surgical intervention as the permanence and psychological effects of the latter are unacceptable for most patients. Degarelix is a third generation antagonist of luteinizing hormone-releasing hormone (LHRH, also termed gona...

2012
Charlotte Guyader Jocelyn Céraline Eléonore Gravier Aurélie Morin Sandrine Michel Eva Erdmann Gonzague de Pinieux Florence Cabon Jean-Pierre Bergerat Marie-France Poupon Stéphane Oudard

Almost all prostate cancers respond to androgen deprivation treatment but many recur. We postulated that risk of hormone escape--frequency and delay--are influenced by hormone therapy modalities. More, hormone therapies induce crucial biological changes involving androgen receptors; some might be targets for escape prevention. We investigated the relationship between the androgen deprivation tr...

2016
Daniel J. Coleman Kathryn Van Hook Carly J. King Jacob Schwartzman Robert Lisac Joshua Urrutia Archana Sehrawat Josha Woodward Nicholas J. Wang Roman Gulati George V. Thomas Tomasz M. Beer Martin Gleave James E. Korkola Lina Gao Laura M. Heiser Joshi J. Alumkal

Prostate cancer is the most commonly diagnosed and second-most lethal cancer among men in the United States. The vast majority of prostate cancer deaths are due to castration-resistant prostate cancer (CRPC) - the lethal form of the disease that has progressed despite therapies that interfere with activation of androgen receptor (AR) signaling. One emergent resistance mechanism to medical castr...

2014
Sofia Gameiro Andressa Ardiani Anna R Kwilas Renee N Donahue James W Hodge

Despite recent advances in diagnosis and therapy, prostate cancer remains the most frequently diagnosed nonskin cancer in the United States and the third leading cause of cancer deaths. Failure of chemotherapies and hormone-deprivation therapies is the major cause of death in patients with castration-resistant prostate cancer (CRPC). Currently, the androgen inhibitors Enzalutamide and Abiratero...

Journal: :Cancer research 2007
Hui Zhang Jian Wang Bo Pang Rui-xia Liang Suping Li Pei-tang Huang Ruoxiang Wang Leland W K Chung Haiyen E Zhau Cuifen Huang Jian-guang Zhou

PC-1/PrLZ gene overexpression has been identified to be associated with prostate cancer progression. Previous studies have revealed that PC-1 possesses transforming activity and confers malignant phenotypes to mouse NIH3T3 cells. However, the functional relevance of PC-1 expression changes during prostate cancer development and progression remains to be evaluated. In this study, gain-of-functio...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید